Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - MELINTA THERAPEUTICS, INC. /NEW/ | cemp-ex312_12.htm |
| 10-K - FORM 10-K - MELINTA THERAPEUTICS, INC. /NEW/ | cemp-10k_20161231.htm |
| EX-32.2 - EX-32.2 - MELINTA THERAPEUTICS, INC. /NEW/ | cemp-ex322_7.htm |
| EX-32.1 - EX-32.1 - MELINTA THERAPEUTICS, INC. /NEW/ | cemp-ex321_11.htm |
| EX-31.1 - EX-31.1 - MELINTA THERAPEUTICS, INC. /NEW/ | cemp-ex311_9.htm |
| EX-10.40 - EX-10.40 - MELINTA THERAPEUTICS, INC. /NEW/ | cemp-ex1040_304.htm |
| EX-10.39 - EX-10.39 - MELINTA THERAPEUTICS, INC. /NEW/ | cemp-ex1039_305.htm |
| EX-10.38 - EX-10.38 - MELINTA THERAPEUTICS, INC. /NEW/ | cemp-ex1038_303.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-181358, No. 333-190891, and No. 333-204560) and Form S-3 (No. 333-203945) of Cempra, Inc. of our report dated February 28, 2017 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
|
/s/PricewaterhouseCoopers LLP |
|
|
Raleigh, North Carolina |
|
|
February 28, 2017 |
|